For each Part B rebatable drug, CMS will identify the applicable payment amount benchmark quarter using the earliest first marketed date of any NDC ever marketed under any FDA application under which any NDCs that have ever been assigned to the billing and payment code as of the applicable calendar quarter have been marketed, as set forth in paragraphs (c)(1) through (3) of this section, as applicable, subject to paragraphs (c)(4) and (5) of this section: (1) For a Part B rebatable drug first approved or licensed by the FDA on or before December 1, 2020, and with a first marketed date on or before December 1, 2020, the payment amount benchmark quarter is the calendar quarter beginning July 1, 2021
We also recognize the importance of continuing to allow beneficiaries to voluntarily identify an ACO professional as their primary clinician for purposes of assignment to a Shared Savings Program ACO, and we reiterate that, based on PY 2024 data, this proposal would impact very few beneficiaries who voluntarily align to Shared Savings Program ACOs (less than .01 percent of all such beneficiaries)
Initial assessment and engagement Comprehensive assessment is a foundation for treatment: Detailed substance use history Assessment of functional impairment Identification of comorbid mental health concerns Evaluation of motivation to change Engagement techniques such as motivational interviewing help clients clarify goals, explore ambivalence, and foster readiness for change
Additionally, the law is making health coverage more affordable for 13 million people because it extends enhanced ACA marketplace subsidies through 2025
Around 80% of the 1.2 billion tobacco users worldwide live in low- and middle-income countries (2) , where the burden of tobacco-related illness and death is heaviest
